Research location

Sioux Falls

South Dakota, United States

Published trials615

Site observations945

Linked trials published615

Page2 / 13

Research activity in Sioux Falls

South Dakota, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 615 trials and 945 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Sioux Falls

615 linked trials · page 2 of 13

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseNCT06283966 · 2024-02-21 · 1 site observation

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)NCT06136624 · 2023-12-31 · 1 site observation

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)NCT06136650 · 2023-12-18 · 1 site observation

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate CancerNCT05946213 · 2023-12-14 · 1 site observation

PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and IIINCT05934487 · 2023-11-29 · 1 site observation

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 3 site observations

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerNCT05929768 · 2023-09-15 · 2 site observations

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsNCT06270706 · 2023-08-30 · 1 site observation

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerNCT05624996 · 2023-07-12 · 2 site observations

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14 · 3 site observations

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)NCT05642572 · 2023-05-05 · 2 site observations

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07 · 2 site observations

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31 · 1 site observation

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · 2022-12-12 · 1 site observation

HF2 Registry - Hemodynamic Frontiers in Heart Failure RegistryNCT06425848 · 2022-10-21 · 1 site observation

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionNCT05334069 · 2022-08-18 · 2 site observations

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid TumorsNCT05377996 · 2022-08-15 · 1 site observation

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaNCT05235165 · 2022-04-01 · 1 site observation

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT04928846 · 2022-03-25 · 1 site observation

Assessment of CCM in HF With Higher Ejection FractionNCT05064709 · 2022-02-03 · 1 site observation

Avera Cancer Sequencing and Analytics Protocol (ASAP)NCT05142033 · 2021-11-01 · 1 site observation

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)NCT04852887 · 2021-06-23 · 2 site observations

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerNCT04614103 · 2021-05-07 · 2 site observations

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerNCT04181060 · 2020-12-28 · 2 site observations

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7NCT04613596 · 2020-12-02 · 1 site observation

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET ImagingNCT04423211 · 2020-10-08 · 2 site observations

General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care DeliveryNCT04477928 · 2020-07-17 · 1 site observation

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848 · 2020-06-16 · 2 site observations

A Study of Sigvotatug Vedotin in Advanced Solid TumorsNCT04389632 · 2020-06-08 · 2 site observations

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)NCT04278404 · 2020-03-05 · 1 site observation

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerNCT04221542 · 2020-03-04 · 1 site observation

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)NCT04165798 · 2019-12-19 · 1 site observation

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)NCT04165070 · 2019-12-19 · 1 site observation

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerNCT03851445 · 2019-02-06 · 2 site observations

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerNCT03723928 · 2018-09-17 · 2 site observations

The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMRNCT03142152 · 2018-01-01 · 1 site observation

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityNCT03418961 · 2017-11-01 · 2 site observations

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)NCT02620852 · 2016-08-31 · 1 site observation

Type 1 Diabetes Extension StudyNCT02734277 · 2016-06-08 · 1 site observation

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordNCT01793168 · 2010-07-01 · 1 site observation

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerNCT01042379 · 2010-03-01 · 1 site observation

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)NCT07680790 · 2026-09-30 · 1 site observation

NOT_YET_RECRUITING

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)NCT06898957 · 2025-05-16 · 1 site observation

ACTIVE_NOT_RECRUITING

An Ophthalmic Safety Study in Patients With Breast CancerNCT06767462 · 2025-03-05 · 1 site observation

ACTIVE_NOT_RECRUITING

Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19 · 2 site observations

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the BrainNCT06500455 · 2024-12-12 · 2 site observations

ACTIVE_NOT_RECRUITING

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung CancerNCT06632327 · 2024-12-11 · 2 site observations

ACTIVE_NOT_RECRUITING

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)NCT06691984 · 2024-12-09 · 1 site observation

ACTIVE_NOT_RECRUITING

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)NCT06635824 · 2024-11-25 · 1 site observation

ACTIVE_NOT_RECRUITING

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic SclerosisNCT06655896 · 2024-10-29 · 1 site observation

ACTIVE_NOT_RECRUITING

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.